NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Enliven Therapeutics, Inc. (ELVN) Stock Analysis

Enliven Therapeutics, Inc. (ELVN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ELVN

$59.32

−$0.33 (−0.55%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELVN with… →

ELVN Key Statistics

As of Sep 4, 2026
Trading
Open
$59.69
Previous Close
$59.65
Day's Range
58.97–59.89
52-Week Range
14.79–62.32
Volume
1.11M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$4.35B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.64
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$103.69M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
73.27M
1-Year Return
+196.45%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.42M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ELVN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+285.19%
2025−31.56%
2024+62.57%
2023−15.40%
2022+81.78%
2021−89.80%
2020 (partial year)+47.00%

As of September 4, 2026.

ELVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$103.69M—
2024$0.00−$89.02M—
2023$0.00−$71.58M—
2022$0.00−$37.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$119.66M−$103.69M—
2024$0.00—−$104.55M−$89.02M—
2023$0.00—−$83.53M−$71.58M—
2022$0.00—−$38.79M−$37.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ELVN Valuation vs Biotechnology Median

Median of 656 stocks
MetricELVNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Enliven Therapeutics, Inc. (ELVN) at $4.35B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 67 employees.

ELVN last closed at $59.32 on September 4, 2026. That is −$0.33 (−0.55%) against the previous close. The 52-week range on file runs from $14.79 to $62.32. The latest close sits 301.22% above that 52-week low.

Financial Health

In fiscal 2025, Enliven Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $103.69M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +196.45%. Across 5 years the annualized return works out at +24.14%. Beta against the wider market is reported at 0.25. Daily returns over the trailing 6 years annualize to a volatility of 84.71%.

Growth & Income

No dividend is on file for ELVN.

Across the complete calendar years on file, 2022 returned +81.78% and 2021 returned −89.80%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the price is +285.19%.

Peer Comparison

Enliven Therapeutics, Inc. (ELVN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enliven Therapeutics, Inc. ELVN $4.35B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Enliven Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Visit website →